Abbott Laboratories (ABT) Cost of Revenue (2009 - 2026)

Abbott Laboratories has disclosed Cost of Revenue across 18 years of filings, most recently posting $5.3 billion for Q2 2026.

• In Q2 2026, Cost of Revenue rose 9.7% year-over-year to $5.3 billion; the TTM figure through Jun 2026 stood at $20.2 billion (up 6.59% YoY), while the FY2025 annual figure was $19.3 billion, up 3.28% from the prior year.
• Cost of Revenue came in at $5.3 billion for Q2 2026 at Abbott Laboratories, up from $4.9 billion in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $5.3 billion in Q2 2026 to a low of $4.3 billion in Q1 2023.
• Average Cost of Revenue over 5 years is $4.7 billion, with a median of $4.7 billion recorded in 2022.
• Year-over-year, Cost of Revenue gained 13.32% in 2022 and decreased 13.15% in 2023.
• Over 5 years, Cost of Revenue stood at $4.6 billion in 2022, then fell by 0.81% to $4.6 billion in 2023, then climbed by 8.47% to $4.9 billion in 2024, then dropped by 0.4% to $4.9 billion in 2025, then climbed by 8.19% to $5.3 billion in 2026.
• Per Business Quant data, the three most recent Cost of Revenue figures were $5.3 billion in Q2 2026, $4.9 billion in Q1 2026, and $4.9 billion in Q4 2025.